PTO- 1478 |
Approved for use through 09/30/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97005028 |
Filing Date: 08/31/2021 |
Input Field |
Entered |
SERIAL NUMBER | 97005028 |
---|---|
MARK INFORMATION | |
*MARK | ALIN |
STANDARD CHARACTERS | YES |
USPTO-GENERATED IMAGE | YES |
LITERAL ELEMENT | ALIN |
MARK STATEMENT | The mark consists of standard characters, without claim to any particular font style, size, or color. |
REGISTER | Principal |
APPLICANT INFORMATION | |
*OWNER OF MARK | Productos Farmaceuticos S.A. de C.V. |
INTERNAL ADDRESS | Lago Tanganica No. 18, Colonia Granada |
*MAILING ADDRESS | Delegacion Miguel Hidalgo |
*CITY | Ciudad de México |
*COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | Mexico |
*ZIP/POSTAL CODE (Required for U.S. and certain international addresses) |
11520 |
*EMAIL ADDRESS | XXXX |
LEGAL ENTITY INFORMATION | |
TYPE | corporation |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY OF INCORPORATION | Mexico |
GOODS AND/OR SERVICES AND BASIS INFORMATION | |
INTERNATIONAL CLASS | 005 |
*IDENTIFICATION | Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, endocrinology for treatment of adrenal failure, thyroiditis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely rheumatology for treatment of rheumatoid arthritis, gout, post-traumatic arthritis, osteoarthritis, synovitis, bursitis, epicondylitis, ankylosing spondylitis, systemic or discoid lupus erythematosus, dermatomyositis, scleroderma, other collagen diseases, other osteoarticular diseases which require chronic corticosteroid administration; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory; immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely dermatology for treatment of pemphigus, erythema multiforme, exfoliative dermatitis, psoriasis, contact dermatitis, keloid lesions, hyperthrophic lichen planus, alopecia areata, urticaria, eczema, rosacea; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, allergology for treatment of bronchial asthma, urticaria, drug or food allergy, hypersensitivity reactions, allergic rhinitis, allergic sinusitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely otolaryngology for treatment of vasomotor rhinitis, other types of rhinitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, ophthalmology for treatment of allergic, acute or chronic conjunctivitis; scleritis, uveitis/iridocyclitis, optic neuritis, corneal infections, keratitis, marginal ulcers, throphic disorders, conjunctival/corneal physical/chemical burning, inflammatory reactions; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, gastroenterology for treatment of ulcerative colitis, regional enteritis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, pulmonology for treatment of bronchoaspiration, Löeffler syndrome, sarcoidosis, interstitial pulmonary fibrosis, chronic bronchitis, emphysema; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely hematology for treatment of autoimmune anemias or thrombocytopenias, leukemias, lymphomas, intravascular coagulation syndrome; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, oncology for treatment of nausea/vomiting associated with cancer chemotherapy prevention; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, miscellaneous for treatment of shock syndromes, cerebral edema |
FILING BASIS | SECTION 44(e) |
FOREIGN REGISTRATION NUMBER |
584291 |
FOREIGN REGISTRATION COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
Mexico |
FOREIGN REGISTRATION DATE |
04/30/1948 |
FOREIGN REGISTRATION EXPIRATION DATE |
04/30/2023 |
DATE FOREIGN REGISTRATION RENEWED (if applicable) |
04/30/2013 |
FOREIGN REGISTRATION FILE NAME(S) | |
ORIGINAL PDF FILE | reg-72208125209-143152647 _._ALIN.pdf |
CONVERTED PDF FILE(S) (9 pages) |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0003.JPG |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0004.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0005.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0006.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0007.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0008.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0009.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0010.JPG | |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0011.JPG | |
STANDARD CHARACTERS OR EQUIVALENT |
NO |
ADDITIONAL STATEMENTS SECTION | |
ACTIVE PRIOR REGISTRATION(S) | The applicant claims ownership of active prior U.S. Registration Number(s) 4824753. |
TRANSLATION | The English translation of ALIN in the mark is lowest. |
ATTORNEY INFORMATION | |
NAME | Jennifer A. Van Kirk |
ATTORNEY DOCKET NUMBER | 154794 |
ATTORNEY BAR MEMBERSHIP NUMBER | XXX |
YEAR OF ADMISSION | XXXX |
U.S. STATE/ COMMONWEALTH/ TERRITORY | XX |
FIRM NAME | Lewis Roca Rothgerber Christie LLP |
STREET | 201 East Washington Street, Suite 1200 |
CITY | Phoenix |
STATE | Arizona |
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY | United States |
ZIP/POSTAL CODE | 85004 |
PHONE | 602-262-5311 |
FAX | 602-262-5747 |
EMAIL ADDRESS | PTO@LEWISROCA.COM |
OTHER APPOINTED ATTORNEY | David Jackson, Rachel Nicholas, Lindsey Schneidman, Daniel Salgado, Chris Underwood |
CORRESPONDENCE INFORMATION | |
NAME | Jennifer A. Van Kirk |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE | PTO@LEWISROCA.COM |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) | JBolliger@LEWISROCA.COM |
FEE INFORMATION | |
APPLICATION FILING OPTION | TEAS Standard |
NUMBER OF CLASSES | 1 |
APPLICATION FOR REGISTRATION PER CLASS | 350 |
*TOTAL FEES DUE | 350 |
*TOTAL FEES PAID | 350 |
SIGNATURE INFORMATION | |
ORIGINAL PDF FILE | hw_72208125209-193310765_ ._ALIN_Signature_Page.pdf |
CONVERTED PDF FILE(S) (1 page) |
\\TICRS\EXPORT18\IMAGEOUT 18\970\050\97005028\xml1\ APP0012.JPG |
SIGNATORY'S NAME | Eryck A. Castillo O. |
SIGNATORY'S POSITION | Legal Representative |
SIGNATORY'S PHONE NUMBER | +52-5555335060 |
SIGNATURE METHOD | Handwritten |
PTO- 1478 |
Approved for use through 09/30/2021. OMB 0651-0009 |
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number |
Serial Number: 97005028 |
Filing Date: 08/31/2021 |
The applicant's current Correspondence Information: |
Jennifer A. Van Kirk |
PRIMARY EMAIL FOR CORRESPONDENCE: PTO@LEWISROCA.COM SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): JBolliger@LEWISROCA.COM Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS). |